American journal of hypertension
-
The relationship between blood pressure (BP) measured, its variability, and risk of cardiovascular events is well established; however, it is not well known whether there is a difference of variability between the four categories of BP status obtained by the comparison of office and home BP measurements: normotension and masked, white-coat, and sustained hypertension. Here, we assessed BP variability (BPV) according to BP status in the elderly. ⋯ In elderly individuals, the short-term variability of BP is similar in masked and sustained hypertension and higher than in normotension and white-coat hypertension. This result suggests the hypothesis that BPV among persons with masked hypertension may contribute to the elevated cardiovascular risk observed in this BP pattern.
-
Hyperuricemia and left ventricular (LV) hypertrophy are prevalent in chronic kidney disease (CKD), but the association of uric acid (UA) and left ventricular mass index (LVMI) with renal outcomes in patients with CKD is unclear. We conducted a study to assess whether the combination of UA and LVMI is associated with renal outcomes in patients with CKD of stages 3-5. ⋯ Our findings show that the combination of a higher UA and LVMI is a risk factor for progression to dialysis and rapid progression of decline in renal function in patients with CKD of stages 3-5.
-
The superiority of prognostic value of blood pressure (BP) measured at central aorta (CBP) over conventional brachial BP measured by cuff-based BP monitors has reignited the development of new noninvasive techniques for estimating CBP. The present study validated the accuracy of CBP measured by a newly developed stand-alone CBP monitor. ⋯ Central SBP, PP, and DBP can be measured accurately by a stand-alone automatic BP monitor.
-
Multicenter Study
Evolution of target organ damage by different values of self-blood pressure measurement in untreated hypertensive patients.
To determine the prognostic value of various self-blood pressure (BP) monitoring (SBPM) cutoff at the time of diagnosis. ⋯ Baseline SBPM values <130/80 mm Hg is associated with better evolution of amount of TOD than SBPM values <135/85 mm Hg. These results would support a clinical trial to test a SBPM threshold <130/80 as an optimal pressure not needing pharmacological treatment among those with CBP ≥ 140/90.
-
Randomized Controlled Trial
Effect of cholecalciferol supplementation during winter months in patients with hypertension: a randomized, placebo-controlled trial.
Low 25-hydroxy-vitamin D (25(OH)D) levels are inversely related to blood pressure (BP) and have been associated with incident hypertension. In people living at northern latitudes diminished cholecalciferol synthesis in the winter increases the risk of vitamin D deficiency. We wanted to test the hypothesis that daily cholecalciferol supplementation in the winter lowers BP in patients with hypertension. ⋯ Cholecalciferol supplementation, by a dose that effectively increased vitamin D levels, did not reduce 24-h BP, although central systolic BP decreased significantly. In a post-hoc subgroup analysis of 92 subjects with baseline p-25(OH)D levels <32 ng/ml, significant decreases in 24-h systolic and diastolic BP occurred during cholecalciferol supplementation.